Quin E Denfeld1, Kenneth M Faulkner2, Mary Roberts Davis1, Beth A Habecker3,4, Christopher V Chien5, Jill M Gelow6, James O Mudd7, Shirin O Hiatt1, Kathleen L Grady8, Christopher S Lee2. 1. School of Nursing, Oregon Health & Science University, SN-ORD, 3455 S.W. U.S. Veterans Hospital Road, Portland, OR 97239-2941, USA. 2. William F. Connell School of Nursing, Boston College, Chestnut Hill, MA, USA. 3. Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA. 4. Department of Chemical Physiology & Biochemistry, Oregon Health & Science University, Portland, OR, USA. 5. Department of Medicine, Division of Cardiology, University of North Carolina, Chapel Hill, NC, USA. 6. Providence Heart & Vascular Institute, Portland, OR, USA. 7. Providence Sacred Heart Medical Center, Spokane, WA, USA. 8. Department of Surgery, Division of Cardiac Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
AIMS: Despite well-known gender differences in heart failure, it is unknown if clinical markers and symptoms differ between women and men after left ventricular assist device (LVAD) implantation. Our aim was to examine gender differences in trajectories of clinical markers (echocardiographic markers and plasma biomarkers) and symptoms from pre- to post-LVAD implantation. METHODS AND RESULTS: This was a secondary analysis of data collected from a study of patients from pre- to 1, 3, and 6 months post-LVAD implantation. Data were collected on left ventricular internal end-diastolic diameter (LVIDd) and ejection fraction (LVEF), plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP), and soluble suppressor of tumorigenicity (sST2). Physical and depressive symptoms were measured using the Heart Failure Somatic Perception Scale and Patient Health Questionnaire-9, respectively. Latent growth curve modelling was used to compare trajectories between women and men. The average age of the sample (n = 98) was 53.3 ± 13.8 years, and most were male (80.6%) and had non-ischaemic aetiology (65.3%). Pre-implantation, women had significantly narrower LVIDd (P < 0.001) and worse physical symptoms (P = 0.041) compared with men. Between pre- and 6 months post-implantation, women had an increase in plasma sST2 followed by a decrease, whereas men had an overall decrease (slope: P = 0.014; quadratic: P = 0.011). Between 1 and 6 months post-implantation, women had a significantly greater increase in LVEF (P = 0.045) but lesser decline in plasmoa NT-proBNP compared with men (P = 0.025). CONCLUSION: Trajectories of clinical markers differed somewhat between women and men, but trajectories of symptoms were similar, indicating some physiologic but not symptomatic gender differences in response to LVAD. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Despite well-known gender differences in heart failure, it is unknown if clinical markers and symptoms differ between women and men after left ventricular assist device (LVAD) implantation. Our aim was to examine gender differences in trajectories of clinical markers (echocardiographic markers and plasma biomarkers) and symptoms from pre- to post-LVAD implantation. METHODS AND RESULTS: This was a secondary analysis of data collected from a study of patients from pre- to 1, 3, and 6 months post-LVAD implantation. Data were collected on left ventricular internal end-diastolic diameter (LVIDd) and ejection fraction (LVEF), plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP), and soluble suppressor of tumorigenicity (sST2). Physical and depressive symptoms were measured using the Heart Failure Somatic Perception Scale and Patient Health Questionnaire-9, respectively. Latent growth curve modelling was used to compare trajectories between women and men. The average age of the sample (n = 98) was 53.3 ± 13.8 years, and most were male (80.6%) and had non-ischaemic aetiology (65.3%). Pre-implantation, women had significantly narrower LVIDd (P < 0.001) and worse physical symptoms (P = 0.041) compared with men. Between pre- and 6 months post-implantation, women had an increase in plasma sST2 followed by a decrease, whereas men had an overall decrease (slope: P = 0.014; quadratic: P = 0.011). Between 1 and 6 months post-implantation, women had a significantly greater increase in LVEF (P = 0.045) but lesser decline in plasmoa NT-proBNP compared with men (P = 0.025). CONCLUSION: Trajectories of clinical markers differed somewhat between women and men, but trajectories of symptoms were similar, indicating some physiologic but not symptomatic gender differences in response to LVAD. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Himabindu Vidula; Valentina Kutyifa; Brent A Johnson; Robert L Strawderman; Donald Harrington; Bronislava Polonsky; Anna Papernov; Jeffrey D Alexis Journal: Am J Cardiol Date: 2018-06-21 Impact factor: 2.778
Authors: Ulrika Ljung Faxén; Lars H Lund; Nicola Orsini; Anna Strömberg; Daniel C Andersson; Cecilia Linde; Ulf Dahlström; Gianluigi Savarese Journal: Int J Cardiol Date: 2019-04-11 Impact factor: 4.164
Authors: Benjamin B Kenigsberg; David T Majure; Farooq H Sheikh; Nana Afari-Armah; Maria Rodrigo; Mark Hofmeyer; Ezequiel J Molina; Zuyue Wang; Steven Boyce; Samer S Najjar; Selma F Mohammed Journal: J Card Fail Date: 2020-03-19 Impact factor: 5.712
Authors: Sven Meyer; Peter van der Meer; Vincent M van Deursen; Tiny Jaarsma; Dirk J van Veldhuisen; Martje H L van der Wal; Hans L Hillege; Adriaan A Voors Journal: Eur Heart J Date: 2013-05-10 Impact factor: 29.983
Authors: Alanna A Morris; Ann Pekarek; Kris Wittersheim; Robert T Cole; Divya Gupta; Duc Nguyen; S Raja Laskar; Javed Butler; Andrew Smith; J David Vega Journal: J Heart Lung Transplant Date: 2015-09-03 Impact factor: 10.247